ESR1 and non-small cell lung carcinoma: Estrogen receptor modulators and aromatase inhibitor may reverse the drug-resistance of platinum based chemotherapy in NSCLC patients and can enhance curative effect of epidermal growth factor receptor tyrosine kinase inhibitor.